CPRX · As filed with the SEC
Catalyst Pharmaceuticals balance sheet, by fiscal year
The statement as Catalyst Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets: | ||||
| Cash and cash equivalents | 709,171,000 | 517,553,000 | 137,636,000 | 298,395,000 |
| Short-term investments | — | — | — | 0 |
| Accounts receivable, net | 126,477,000 | 65,476,000 | 53,514,000 | 10,439,000 |
| Inventory, net | 37,166,000 | 19,541,000 | 15,644,000 | 6,805,000 |
| Prepaid expenses and other current assets | 21,216,000 | 21,039,000 | 12,535,000 | 5,158,000 |
| Total current assets | 894,030,000 | 623,609,000 | 219,329,000 | 320,797,000 |
| Operating lease right-of-use asset, net | 1,935,000 | 2,230,000 | 2,508,000 | 2,770,000 |
| Property and equipment, net | 1,037,000 | 1,354,000 | 1,195,000 | 847,000 |
| License and acquired intangibles, net | 131,674,000 | 156,672,000 | 194,049,000 | 32,471,000 |
| Deferred tax assets, net | 52,767,000 | 45,982,000 | 36,544,000 | 18,736,000 |
| Deposits | — | — | — | 9,000 |
| Investment in equity securities | 22,536,000 | 21,564,000 | 16,489,000 | — |
| Total assets | 1,103,979,000 | 851,411,000 | 470,114,000 | 375,630,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
| Current Liabilities: | ||||
| Accounts payable | 11,202,000 | 16,593,000 | 14,795,000 | 3,975,000 |
| Accrued expenses and other liabilities | 135,950,000 | 104,085,000 | 61,268,000 | 53,613,000 |
| Total current liabilities | 147,152,000 | 120,678,000 | 76,063,000 | 57,588,000 |
| Operating lease liability, net of current portion | 2,350,000 | 2,786,000 | 3,188,000 | 3,557,000 |
| Other non-current liabilities | 209,000 | 315,000 | 2,982,000 | 14,064,000 |
| Total liabilities | 149,711,000 | 123,779,000 | 82,233,000 | 75,209,000 |
| Stockholders' Equity: | ||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 122,513,621 shares and 120,879,099 shares issued and outstanding at December 31 2025 and 2024, respectively | 123,000 | 121,000 | 107,000 | 105,000 |
| Additional paid-in capital | 479,957,000 | 442,286,000 | 266,488,000 | 250,430,000 |
| Retained earnings | 474,188,000 | 285,161,000 | 121,272,000 | 49,862,000 |
| Accumulated other comprehensive income (Note 4) | 0 | 64,000 | 14,000 | 24,000 |
| Total stockholders' equity | 954,268,000 | 727,632,000 | 387,881,000 | 300,421,000 |
| Total liabilities and stockholders' equity | 1,103,979,000 | 851,411,000 | 470,114,000 | 375,630,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.